Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

15d ago, source:

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...

Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)

4d ago, source:

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN – Research Report), Abbott Labs ...

Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)

3h ago, source:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AstraZeneca (AZN – Research Report) and ...

Hepion ends Phase 2 study for NASH drug due to cash restraints

on MSN ago, source:

Hepion Pharmaceuticals (NASDAQ:HEPA) said it has begun winding down its ASCEND-NASH Phase 2 study for its drug rencofilstat ...

PTC Therapeutics: Q1 Earnings Snapshot

18h ago, source:

SOUTH PLAINFIELD, N.J. (AP) — SOUTH PLAINFIELD, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $91.6 million in its first quarter. The South Plainfield, New Jersey-based ...

Intra-Cellular depression data has investors feeling good

9d ago, source: The Pharma Letter

Shares in US CNS specialist Intra-Cellular Therapies (Nasdaq: ITCI) closed 23% higher on Tuesday. This followed the New York firm’s presentation of positive top-line results from Study 501 evaluating ...

Analyzing the Price-to-Earnings Ratio of Cullinan Therapeutics Inc (CGEM)

4d ago, source: newsheater

Based on Cullinan Therapeutics Inc (CGEM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -37.4. The debt to equity ...

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

1mon ago, source:

Madrigal Pharmaceuticals(NASDAQ: MDGL) just experienced such an event. Last Thursday, the company won U.S. Food and Drug (FDA) approval for the first drug targeting the multibillion-dollar market for ...

Phase II miss in PD cognitive impairment clips Sage

8d ago, source: BioWorld

Sage Therapeutics Inc. shares (NASDAQ:SAGE) were trading at $12.52, down $3.11, or almost 20%, after the Cambridge, Mass.-based firm rolled out top-line data from Precedent, a double-blind, ...